London Startup to Trial Drug to Prevent Cancer Therapy Side-Effect ‘Cytokine Storm’

Why It Matters

If successful, POLB 001 could eliminate the costly, life‑threatening CRS complication, expanding access to high‑price immunotherapies and easing capacity pressures on the NHS and other health systems.

Key Takeaways

• POLB 001 aims to prevent cytokine release syndrome in blood‑cancer patients
• Trial will enroll 30 patients across six NHS hospitals using Tecvayli
• Preventing CRS could shift care from specialist centers to community hospitals
• Estimated $10 bn market based on $20,000 price and 500k patients by 2031
• Poolbeg also develops a GLP‑1 weight‑loss pill for obesity trials

Pulse Analysis

Cytokine release syndrome has emerged as the most serious safety hurdle for next‑generation cancer immunotherapies, affecting roughly 70 % of patients receiving CAR‑T or bispecific antibodies. While these treatments deliver unprecedented response rates in multiple myeloma and diffuse large B‑cell lymphoma, the unpredictable immune surge can trigger fever, organ failure and intensive‑care admission. The absence of a prophylactic drug forces clinicians to administer therapy only in specialised cancer centres, limiting geographic access and inflating overall treatment costs.

Poolbeg Pharma’s oral candidate POLB 001 seeks to blunt the signalling pathway that triggers CRS, allowing patients to start immunotherapy from home under routine monitoring. The upcoming trial, led by the University of Manchester and Christie NHS Foundation Trust, will test the drug in 30 patients across six NHS sites, with interim results slated for the end of summer. By averting CRS, the company estimates a $10 bn market opportunity at a $20,000 price point, while the NHS could save millions by reducing the need for prolonged specialist‑hospital stays and intensive‑care resources.

Beyond CRS prevention, Poolbeg is diversifying its pipeline with a GLP‑1‑based obesity pill, reflecting a broader trend of biotech firms leveraging platform technologies across therapeutic areas. The firm raised roughly $33 million (£25 million) on the London AIM market, underscoring investor appetite for innovative, cost‑saving solutions in oncology and metabolic disease. If POLB 001 demonstrates efficacy, it could set a new standard for managing immunotherapy side effects, catalysing wider adoption of high‑price cancer drugs and reshaping reimbursement models across Europe and the United States.